2004 Silex commissioned the world’s first silicon laser
2009 Silex announced in June the acquisition of
the Sydney Olympic Park (SOP) solar PV panel manufacturing facility - the only PV panel plant Translucent secured its first US Patent for ‘optical silicon’ and filed patents for Silicon -on-Insulator (SOI) and dielectric substrates for the silicon gLE submitted a license application to the US nrC to build and operate a commercial SILEX uranium-enrichment facility in Wilmington N.C In august the nrC announced it had accepted Translucent wins a US Defence Department the license application, triggering a ~30 months DarPa grant to help develop the ‘optical silicon’ technology, under DarPa’s Electronics and Photonics Integrated Circuits (EPIC) Program.
gLE in July announced the on-schedule start-up of the Test Loop to evaluate the next-generation Subsidiary ChronoLogic wins a Federal government SILEX uranium enrichment technology.
“Commercial ready grant” for its novel ‘USB-inSyncTM’ Data acquisition technology ($1.2M for three years).
2010 Silex acquired the business assets of Melbourne-
based Solar Systems group (SSG) in March for $20M. SSG’s concentrating PV technology is Silex and the General Electric Company sign applicable to large utility-scale solar power an exclusive Commercialisation and License generation, using its unique ultra-high efficiency agreement for the SILEX Uranium Enrichment Technology in May, with US Government authorisations received in October.
gLE and Silex announced the successful completion of the Test Loop initial measurement program in april.
2007 Transfer of the SILEX Uranium Enrichment project
to GE’s Wilmington, North Carolina nuclear fuel The Silex Solar PV Panel manufacturing plant plant was completed in the first half of 2007. officially opened at Sydney Olympic Park in April. Hitachi joined gE as project partner.
In December the company undertook an expansion of the plant to 35MW annual production capacity.
gE-Hitachi Signs Letters of Intent for uranium enrichment services and support using the SILEX 2011 Silex Systems successfully completed a capital
Technology with Exelon and Entergy - the two raising of $89 million and a share purchase plan largest nuclear power utilities in the US.
which raised a further $20 million (total capital raised of $109 million).
Silex successfully completes a $50 million capital raising on market in October.
Solar Systems announced in March the commencement of preliminary activities for 2008 global Laser Enrichment (gLE), formed as
construction of a 2MW Pilot Demonstration a subsidiary of GE Hitachi Nuclear Energy Facility at Mildura – the precursor to a 100MW (gEH) to commercialise the SILEX Technology, Solar Power Station, using its unique ultra-high announced that it had selected its Wilmington, efficiency ‘Dense array’ technology.
N.C., headquarters site for the first potential commercial SILEX uranium enrichment facility.
Completion of a $75 million Federal Government funding package for the 100MW Mildura solar power gLE was notified that the U.S. nuclear regulatory station was announced by Solar Systems in June. A Commission (nrC) approved a license to operate $50 million package from the Victorian Government the test Loop for the next generation SILEX laser for the same project was confirmed in 2010.
Silex Solar announced a major restructure of its GEH and Cameco Corp. (NYSE:CCJ) announced silicon PV panel business in August, including the that Cameco Corporation, the world’s largest shutdown of cell production. This action was required uranium producer, had joined the gLE venture. to improve competitiveness in a challenging market.
Cameco paid US$123.8 million for a 24% stake in gLE. gE retained 51% ownership with Hitachi The US nrC released a revised schedule in September for the licensing of gLE’s first commercial enrichment production plant using the SILEX Technology. The nrC decision could extend up to six months to Q3 CY 2012.



Een kwart eeuw wiegendood in Nederland De incidentie van wiegendood is in ons land vanaf oktoberde statistiek van doodsoorzaken van het CBS. De preva-1987 sterk afgenomen, parallel aan de bestrijding van delenties van risicofactoren bij wiegendoodkinderen (0–23gewoonte om zuigelingen op hun buik te laten slapen. maanden) en in de algemene bevolking bij zuigelingen vanSinds 1987 zijn mee

Miolo rpm 124-3 (miolo 2).indd

Parkinson’s disease and dopamine transporter neuroimaging – a critical review Laboratório Interdisciplinar de Neuroimagem e Cognição (LiNC), Universidade Federal de São Paulo and Instituto Israelita de Ensino e Pesquisa (IIEP), Hospital Israelita Albert Einstein (HIAE), São Paulo, Brazil disease patients manifest symptoms only when 50 to 80% of the nigrostriatal neurons a

Copyright © 2010-2018 Pharmacy Drugs Pdf